Psyence Group Inc. (PSYGF)
USD 0.12
(0.0%)
USD 0.12
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 15.1 Million CAD | 466.35% |
| 2023 | 2.66 Million CAD | 62.3% |
| 2022 | 1.64 Million CAD | 1101.6% |
| 2021 | 136.76 Thousand CAD | 126.11% |
| 2020 | 60.48 Thousand CAD | -18.16% |
| 2019 | 73.91 Thousand CAD | -36.06% |
| 2018 | 115.6 Thousand CAD | 20.78% |
| 2017 | 95.72 Thousand CAD | 54.47% |
| 2016 | 61.96 Thousand CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 FY | 15.1 Million CAD | 466.35% |
| 2024 Q4 | 15.1 Million CAD | 974.6% |
| 2024 Q1 | 1.91 Million CAD | -28.38% |
| 2024 Q3 | 1.4 Million CAD | -41.95% |
| 2024 Q2 | 2.42 Million CAD | 26.77% |
| 2023 Q2 | 1.72 Million CAD | -3.36% |
| 2023 FY | 2.66 Million CAD | 62.3% |
| 2023 Q4 | 2.66 Million CAD | 48.77% |
| 2023 Q3 | 1.79 Million CAD | 4.09% |
| 2023 Q1 | 1.78 Million CAD | 8.46% |
| 2022 Q3 | 617.13 Thousand CAD | 209.74% |
| 2022 FY | 1.64 Million CAD | 1101.6% |
| 2022 Q1 | 279.05 Thousand CAD | 95488.04% |
| 2022 Q4 | 1.64 Million CAD | 166.3% |
| 2022 Q2 | 199.24 Thousand CAD | -28.6% |
| 2021 Q2 | 54.93 Thousand CAD | 0.0% |
| 2021 FY | 136.76 Thousand CAD | 126.11% |
| 2021 Q4 | 291.93 CAD | -99.79% |
| 2021 Q3 | 136.76 Thousand CAD | 148.99% |
| 2020 FY | 60.48 Thousand CAD | -18.16% |
| 2019 FY | 73.91 Thousand CAD | -36.06% |
| 2018 FY | 115.6 Thousand CAD | 20.78% |
| 2017 FY | 95.72 Thousand CAD | 54.47% |
| 2016 FY | 61.96 Thousand CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AstraZeneca PLC | 61.86 Billion USD | 99.976% |
| Bristol-Myers Squibb Company PFD CONV 2 | 65.67 Billion USD | 99.977% |
| CSPC Pharmaceutical Group Limited | 1.53 Billion USD | 99.019% |
| Clarus Therapeutics Holdings, Inc. | 67.62 Million USD | 77.663% |
| Novartis AG | 53.19 Billion USD | 99.972% |
| PT Kalbe Farma Tbk. | 255.94 Million USD | 94.098% |